DF/HCC

(redirected from Dana-Farber/Harvard Cancer Center)
Also found in: Wikipedia.
AcronymDefinition
DF/HCCDana-Farber/Harvard Cancer Center (also seen as DFHCC)
References in periodicals archive ?
Verastem dosed the first patient in a multicenter Phase I/II clinical trial at the Dana-Farber/Harvard Cancer Center of duvelisib in combination with venetoclax in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.
Shapiro is Professor of Medicine at the Dana-Farber Cancer Institute, where he is director of the Early Drug Development Center, Clinical director of the Center for DNA Damage and Repair and co-Leader of the Dana-Farber/Harvard Cancer Center Program in Developmental Therapeutics.
Currently, Dr Garraway is director of the Joint Center for Cancer Precision Medicine as well as co-leader of the Cancer Genetics Programme at the Dana-Farber/Harvard Cancer Center.
He is coinvestigator of 3 National Institutes of Health grants and is currently the codirector of the Specialized Programs of Research Excellence in Lung Cancer Grant at the Dana-Farber/Harvard Cancer Center. He has authored and coauthored more than 70 articles published in peer-reviewed journals and numerous book chapters in textbooks with a focus on lung cancer.
It is a founding member of the Dana-Farber/Harvard Cancer Center (DF/HCC), designated a comprehensive cancer center by the National Cancer Institute.
National Cancer Institute, the Cancer Genetics Network, the Dana-Farber/Harvard Cancer Center, and the U.K.
Holmes of the Dana-Farber/Harvard Cancer Center in Boston, who was the formal discussant of the presentation.
The addition of PBIO is expected to greatly benefit the Center for Personalized Cancer Therapy, a joint UMass Boston venture with the Dana-Farber/Harvard Cancer Center to be launched within the VDC.
Located in Boston, Dana-Farber Cancer Institute is a principal teaching affiliate of the Harvard Medical School and a founding member of Dana-Farber/Harvard Cancer Center, a National Cancer Institute-designated comprehensive cancer center.
It is a founding member of the Dana-Farber/Harvard Cancer Center, a designated comprehensive cancer center by the National Cancer Institute.
Trovagene have received Institutional Review Board approval from Dana-Farber/Harvard Cancer Center and its Phase 2 clinical trial of PCM-075 in combination with Zytiga and prednisone in metastatic Castration-Resistant Prostate Cancer is officially activated and recruiting patients.